ID int64 6 67 | author stringclasses 23
values | year int64 2.01k 2.02k | cancerType stringclasses 13
values | cellLine stringclasses 27
values | time int64 8 144 | coumarin stringclasses 2
values | coumarinDose float64 0.1 335 | viability float64 3.66 109 | viabilitySD float64 0.5 24.6 | viabilityN int64 2 6 | control float64 77.3 111 | controlSD float64 0.86 12.5 | controlN int64 2 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
48 | Moon et al. | 2,015 | Gastric | MKN-45 | 48 | Auraptene | 25 | 109.35 | 13.21 | 3 | 100 | 6.6 | 3 |
48 | Moon et al. | 2,015 | Gastric | MKN-45 | 48 | Auraptene | 50 | 67.88 | 14.68 | 3 | 100 | 6.6 | 3 |
48 | Moon et al. | 2,015 | Gastric | MKN-45 | 48 | Auraptene | 100 | 35.59 | 3.67 | 3 | 100 | 6.6 | 3 |
48 | Moon et al. | 2,015 | Gastric | SNU-1 | 48 | Auraptene | 12.5 | 66.42 | 15.78 | 3 | 100 | 3.67 | 3 |
48 | Moon et al. | 2,015 | Gastric | SNU-1 | 48 | Auraptene | 25 | 44.77 | 10.27 | 3 | 100 | 3.67 | 3 |
48 | Moon et al. | 2,015 | Gastric | SNU-1 | 48 | Auraptene | 50 | 29.35 | 1.47 | 3 | 100 | 3.67 | 3 |
48 | Moon et al. | 2,015 | Gastric | SNU-1 | 48 | Auraptene | 100 | 29.72 | 1.1 | 3 | 100 | 3.67 | 3 |
48 | Moon et al. | 2,015 | Gastric | SNU-16 | 48 | Auraptene | 12.5 | 86.97 | 3.3 | 3 | 100 | 8.07 | 3 |
48 | Moon et al. | 2,015 | Gastric | SNU-16 | 48 | Auraptene | 25 | 84.4 | 4.4 | 3 | 100 | 8.07 | 3 |
48 | Moon et al. | 2,015 | Gastric | SNU-16 | 48 | Auraptene | 50 | 48.44 | 3.67 | 3 | 100 | 8.07 | 3 |
48 | Moon et al. | 2,015 | Gastric | SNU-16 | 48 | Auraptene | 100 | 44.03 | 4.41 | 3 | 100 | 8.07 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 1 | 89.04 | 6.18 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 2 | 98.87 | 10.68 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 5 | 100.28 | 10.67 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 10 | 68.25 | 8.99 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 15 | 25.28 | 5.33 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 20 | 18.82 | 3.93 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 25 | 15.73 | 1.96 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 30 | 15.16 | 2.53 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 40 | 16.57 | 1.96 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MDA-MB231 | 24 | Auraptene | 50 | 17.97 | 2.53 | 3 | 100 | 9.01 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 1 | 107.26 | 4.93 | 3 | 100 | 3.36 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 2 | 106.84 | 6.17 | 3 | 100 | 3.36 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 5 | 95.75 | 4.11 | 3 | 100 | 3.36 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 10 | 96.98 | 6.99 | 3 | 100 | 3.36 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 15 | 76.84 | 4.11 | 3 | 100 | 3.36 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 20 | 74.79 | 5.34 | 3 | 100 | 3.36 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 25 | 65.34 | 5.75 | 3 | 100 | 3.36 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 30 | 56.71 | 5.34 | 3 | 100 | 3.36 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 40 | 51.78 | 4.52 | 3 | 100 | 3.36 | 3 |
49 | Krishnan et al. | 2,009 | Breast | MCF-7 | 24 | Auraptene | 50 | 51.36 | 5.35 | 3 | 100 | 3.36 | 3 |
51 | Goodarzi et al. | 2,021 | Leukemia/Lymphoma | MT-2 | 48 | Auraptene | 10 | 98.62 | 1.83 | 3 | 99.9 | 1.76 | 3 |
51 | Goodarzi et al. | 2,021 | Leukemia/Lymphoma | MT-2 | 48 | Auraptene | 20 | 100 | 4.3 | 3 | 99.9 | 1.76 | 3 |
51 | Goodarzi et al. | 2,021 | Leukemia/Lymphoma | MT-2 | 72 | Auraptene | 10 | 97.8 | 1.74 | 3 | 99.4 | 1.51 | 3 |
51 | Goodarzi et al. | 2,021 | Leukemia/Lymphoma | MT-2 | 72 | Auraptene | 20 | 95.7 | 4.3 | 3 | 99.4 | 1.51 | 3 |
51 | Goodarzi et al. | 2,021 | Leukemia/Lymphoma | MT-2 | 72 | Auraptene | 40 | 79.2 | 10.7 | 3 | 99.4 | 1.51 | 3 |
51 | Goodarzi et al. | 2,021 | Leukemia/Lymphoma | MT-2 | 96 | Auraptene | 10 | 81.2 | 15.58 | 3 | 98.9 | 2.01 | 3 |
51 | Goodarzi et al. | 2,021 | Leukemia/Lymphoma | MT-2 | 96 | Auraptene | 20 | 87.3 | 3.52 | 3 | 98.9 | 2.01 | 3 |
51 | Goodarzi et al. | 2,021 | Leukemia/Lymphoma | MT-2 | 96 | Auraptene | 40 | 76 | 11.61 | 3 | 98.9 | 2.01 | 3 |
52 | Li et al. | 2,013 | Breast | T47D | 48 | Auraptene | 1 | 90.2 | 2.45 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | T47D | 48 | Auraptene | 3 | 88.73 | 4.9 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | T47D | 48 | Auraptene | 10 | 78.93 | 3.93 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | T47D | 48 | Auraptene | 30 | 52.46 | 2.46 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | T47D | 144 | Auraptene | 1 | 87.09 | 1.44 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | T47D | 144 | Auraptene | 3 | 84.22 | 1.44 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | T47D | 144 | Auraptene | 10 | 57.9 | 2.87 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | T47D | 144 | Auraptene | 30 | 19.14 | 1.43 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | MDA-MB231 | 48 | Auraptene | 1 | 99.53 | 3.3 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | MDA-MB231 | 48 | Auraptene | 3 | 100 | 2.8 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | MDA-MB231 | 48 | Auraptene | 10 | 98.12 | 2.82 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | MDA-MB231 | 48 | Auraptene | 30 | 87.74 | 1.89 | 3 | 100 | 3.36 | 3 |
52 | Li et al. | 2,013 | Breast | MDA-MB231 | 144 | Auraptene | 30 | 71 | 0.5 | 3 | 100 | 3.36 | 3 |
59 | Charmforoshan et al. | 2,019 | Breast | MCF-7 | 48 | Auraptene | 61.3 | 50 | 3.65 | 3 | 100 | 3.36 | 3 |
59 | Charmforoshan et al. | 2,019 | Breast | MCF-7 | 48 | Auraptene | 103.8 | 75 | 4.79 | 3 | 100 | 3.36 | 3 |
59 | Charmforoshan et al. | 2,019 | Breast | MCF-7 | 48 | Auraptene | 207.7 | 49.24 | 2.52 | 3 | 100 | 3.36 | 3 |
60 | Epifano et al. | 2,023 | Neuroblastoma | SHSY-5Y | 24 | Auraptene | 12.25 | 81.44 | 6.09 | 6 | 100 | 3.36 | 6 |
60 | Epifano et al. | 2,023 | Neuroblastoma | SHSY-5Y | 24 | Auraptene | 25 | 75.34 | 5.54 | 6 | 100 | 3.36 | 6 |
60 | Epifano et al. | 2,023 | Neuroblastoma | SHSY-5Y | 24 | Auraptene | 50 | 62.04 | 5.81 | 6 | 100 | 3.36 | 6 |
61 | Gkionis et al. | 2,021 | Breast | MCF-7 | 48 | Auraptene | 70 | 50 | 6.82 | 2 | 100 | 3.36 | 2 |
61 | Gkionis et al. | 2,021 | Breast | MDA-MB231 | 48 | Auraptene | 60 | 50 | 6.82 | 2 | 100 | 3.36 | 2 |
61 | Gkionis et al. | 2,021 | Breast | MCF-7 | 48 | Auraptene | 0.1 | 103.26 | 12.76 | 2 | 100 | 3.36 | 2 |
61 | Gkionis et al. | 2,021 | Breast | MCF-7 | 48 | Auraptene | 1 | 99.11 | 7.12 | 2 | 100 | 3.36 | 2 |
61 | Gkionis et al. | 2,021 | Breast | MCF-7 | 48 | Auraptene | 10 | 89.91 | 6.23 | 2 | 100 | 3.36 | 2 |
61 | Gkionis et al. | 2,021 | Breast | MCF-7 | 48 | Auraptene | 50 | 70.91 | 4.75 | 2 | 100 | 3.36 | 2 |
61 | Gkionis et al. | 2,021 | Breast | MCF-7 | 48 | Auraptene | 100 | 26.11 | 6.82 | 2 | 100 | 3.36 | 2 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 24 | Auraptene | 12.5 | 105.25 | 3.94 | 3 | 99.9 | 1.97 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 24 | Auraptene | 25 | 106.37 | 8.45 | 3 | 99.9 | 1.97 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 24 | Auraptene | 50 | 84.99 | 5.34 | 3 | 99.9 | 1.97 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 24 | Auraptene | 100 | 75.42 | 2.53 | 3 | 99.9 | 1.97 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 48 | Auraptene | 12.5 | 80.44 | 1.59 | 3 | 99.82 | 2.39 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 48 | Auraptene | 25 | 61.85 | 1.86 | 3 | 99.82 | 2.39 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 48 | Auraptene | 50 | 50.7 | 1.86 | 3 | 99.82 | 2.39 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 48 | Auraptene | 100 | 38.76 | 1.59 | 3 | 99.82 | 2.39 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 72 | Auraptene | 12.5 | 76.01 | 1.75 | 3 | 100 | 2.04 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 72 | Auraptene | 25 | 59.12 | 2.91 | 3 | 100 | 2.04 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 72 | Auraptene | 50 | 46.89 | 3.2 | 3 | 100 | 2.04 | 3 |
62 | Jalilzade et al. | 2,020 | Colon | HT-29 | 72 | Auraptene | 100 | 42.52 | 5.53 | 3 | 100 | 2.04 | 3 |
63 | Lee et al. | 2,017 | Prostate | PC3 | 24 | Auraptene | 15 | 99.68 | 2.02 | 3 | 100 | 3.36 | 3 |
63 | Lee et al. | 2,017 | Prostate | PC3 | 24 | Auraptene | 30 | 80.42 | 7.84 | 3 | 100 | 3.36 | 3 |
63 | Lee et al. | 2,017 | Prostate | PC3 | 24 | Auraptene | 60 | 63.39 | 3.36 | 3 | 100 | 3.36 | 3 |
63 | Lee et al. | 2,017 | Prostate | PC3 | 24 | Auraptene | 90 | 60.48 | 2.91 | 3 | 100 | 3.36 | 3 |
63 | Lee et al. | 2,017 | Prostate | PC3 | 24 | Auraptene | 120 | 43.68 | 2.46 | 3 | 100 | 3.36 | 3 |
63 | Lee et al. | 2,017 | Prostate | LNCaP | 24 | Auraptene | 15 | 87.81 | 3.59 | 3 | 100 | 2.24 | 3 |
63 | Lee et al. | 2,017 | Prostate | LNCaP | 24 | Auraptene | 30 | 79.3 | 1.57 | 3 | 100 | 2.24 | 3 |
63 | Lee et al. | 2,017 | Prostate | LNCaP | 24 | Auraptene | 60 | 70.34 | 1.56 | 3 | 100 | 2.24 | 3 |
63 | Lee et al. | 2,017 | Prostate | LNCaP | 24 | Auraptene | 90 | 62.72 | 3.36 | 3 | 100 | 2.24 | 3 |
63 | Lee et al. | 2,017 | Prostate | LNCaP | 24 | Auraptene | 120 | 57.34 | 2.24 | 3 | 100 | 2.24 | 3 |
63 | Lee et al. | 2,017 | Prostate | DU145 | 24 | Auraptene | 15 | 72.04 | 2.31 | 3 | 100 | 2.8 | 3 |
63 | Lee et al. | 2,017 | Prostate | DU145 | 24 | Auraptene | 30 | 60.21 | 3.58 | 3 | 100 | 2.8 | 3 |
63 | Lee et al. | 2,017 | Prostate | DU145 | 24 | Auraptene | 60 | 56.45 | 2.33 | 3 | 100 | 2.8 | 3 |
63 | Lee et al. | 2,017 | Prostate | DU145 | 24 | Auraptene | 90 | 41.03 | 2.28 | 3 | 100 | 2.8 | 3 |
63 | Lee et al. | 2,017 | Prostate | DU145 | 24 | Auraptene | 120 | 33.15 | 5.02 | 3 | 100 | 2.8 | 3 |
64 | Izadi et al. | 2,023 | Glioblastoma | U87 | 24 | Auraptene | 40 | 89.38 | 11.02 | 3 | 100 | 3.36 | 3 |
64 | Izadi et al. | 2,023 | Glioblastoma | U87 | 24 | Auraptene | 80 | 80.81 | 2.04 | 3 | 100 | 3.36 | 3 |
64 | Izadi et al. | 2,023 | Glioblastoma | U87 | 24 | Auraptene | 160 | 77.55 | 2.45 | 3 | 100 | 3.36 | 3 |
64 | Izadi et al. | 2,023 | Glioblastoma | U87 | 24 | Auraptene | 330 | 46.53 | 2.45 | 3 | 100 | 3.36 | 3 |
66 | Shiran et al. | 2,021 | Breast | MDA-MB231 | 24 | Auraptene | 6.25 | 94.44 | 2.96 | 3 | 100 | 3.36 | 3 |
66 | Shiran et al. | 2,021 | Breast | MDA-MB231 | 24 | Auraptene | 12.5 | 92.59 | 1.48 | 3 | 100 | 3.36 | 3 |
66 | Shiran et al. | 2,021 | Breast | MDA-MB231 | 24 | Auraptene | 25 | 87.03 | 3.34 | 3 | 100 | 3.36 | 3 |
66 | Shiran et al. | 2,021 | Breast | MDA-MB231 | 24 | Auraptene | 50 | 84.07 | 2.59 | 3 | 100 | 3.36 | 3 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.